...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of gastroenterology and hepatology >Re-treatment with interferon-beta of patients with chronic hepatitis C virus infection.
【24h】

Re-treatment with interferon-beta of patients with chronic hepatitis C virus infection.

机译：慢性丙型肝炎病毒感染患者的β-干扰素治疗。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To evaluate the efficacy of interferon-beta (IFN-beta) in the re-treatment of patients with chronic hepatitis C who did not respond to IFN-alpha monotherapy. PATIENTS AND METHODS: Thirty patients (24 men and six women; mean age, 41 +/- 13 (SD) years; range, 23-62 years), with chronic hepatitis C that was non-responsive to a standard course of IFN-alpha therapy, were re-treated with recombinant human IFN-beta-1a. All patients received IFN-beta, 12 MIU subcutaneously, three times weekly for 3 months, after which time patients' responses were evaluated. Responders (normal alanine aminotransferase, and negative for serum hepatitis C virus RNA) continued to receive IFN-beta, 12 MIU, for a further 3 months. Non-responders had their dose increased to 18 MIU for the remaining 3 months of treatment. After 6 months of treatment, therapy was stopped and patients were followed-up for a further 6 months. RESULTS: Overall, six (20%) of the 30 patients exhibited a response at the end of treatment. One patient (3.3%) maintained a sustained virological response at the end of post-treatment follow-up. CONCLUSIONS: Treatment with recombinant IFN-beta, at doses of up to 18 MIU for 6 months, is safe and well tolerated. However, the results of the trial do not support the use of IFN-beta monotherapy in patients with chronic hepatitis C that is resistant to IFN-alpha.
机译：目的：评价干扰素-β（IFN-β）在对干扰素-α单药治疗无效的慢性丙型肝炎患者的再治疗中的疗效。患者与方法：30例慢性丙型肝炎对标准IFN-疗程无反应的患者（24名男性和6名女性;平均年龄41 +/- 13（SD）岁;范围23-62岁）。用重组人IFN-β-1a重新治疗α疗法。所有患者皮下注射IFN-beta，12 MIU，每周3次，共3个月，此后评估患者的反应。应答者（丙氨酸转氨酶正常，血清丙型肝炎病毒RNA阴性）继续接受IFN-beta 12 MIU，持续3个月。在剩余的3个月的治疗中，无反应者的剂量增加至18 MIU。治疗6个月后，停止治疗，并对患者进行了6个月的随访。结果：总体而言，30例患者中有6例（20％）在治疗结束时表现出缓解。一名患者（3.3％）在治疗后的随访结束时保持了持续的病毒学应答。结论：重组干扰素-β的治疗剂量最高为18 MIU，为期6个月，是安全且耐受性良好的。但是，该试验结果不支持在对IFN-α耐药的慢性丙型肝炎患者中使用IFN-β单一疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号